[1]Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs.Expert Opin Drug Saf,2006,5(2):231-249.[2]Agal S,Baijal R,Pramanik S,et al.Monitoring and management of antituberculosis drug induced hepotoxicity. J Gastroenterol Hepatol,2005,20(11):1745-1752.[3]陈佳怀, 许卓磐.汕头市区1998—2002年初治涂阳肺结核病人抗结核治疗引起肝损害情况分析.中国防痨杂志, 2004,26(4): 242-244.[4]中华人民共和国卫生部疾病预防控制局,中华人民共和国卫生部医政司,中国疾病预防控制中心.中国结核病防治规划实施工作指南(2008年版).北京:中国协和医科大学出版社,2009:27-53.[5]Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol,1990,11(2):272-276.[6]唐神结,高文.临床结核病学.北京:人民卫生出版社,2011:195.[7]中华医学会消化病学分会肝胆疾病协作组.急性药物性肝损伤诊治建议(草案).中华消化杂志,2007,27(11):765-767.[8]夏愔愔,詹思延.国内抗结核药物不良反应发生率的综合分析.中华结核和呼吸杂志,2007,30(6):419-423.[9]Shang P, Xia Y, Liu F, et al.Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China.PLoS One,2011,6(7): e21836.[10]房宏霞,武姗姗,吕晓珍,等.抗结核治疗期间患者出现肝损伤相关症状与致肝损伤的关系分析.中国防痨杂志,2013,35(10): 816-822. |